What the research found

Visceral fat—the deep abdominal fat surrounding organs that you cannot see or pinch—accumulates rapidly in women during the menopause transition, separate from changes in overall weight or subcutaneous fat. Population studies link visceral fat accumulation to increased cardiovascular disease and cancer risk independent of BMI. Tissue analysis suggests visceral fat in postmenopausal women becomes metabolically active, with larger fat cells, increased immune infiltration, and associations with reduced insulin sensitivity.

The timing is specific: visceral fat begins climbing around 2 years before the final menstrual period, then rises steeply at roughly 8% annually. This happens even as total weight remains stable—studies tracking body composition show fat mass doubling its rate of gain while lean mass plateaus and declines, a shift that bathroom scales completely miss. The mechanism isn't fully clear, though falling estrogen drives the shift toward abdominal fat storage; interestingly, bioavailable testosterone may also influence visceral fat distribution.

Why it matters for you

If you're tracking body composition or waist circumference on MyKine, visceral accumulation is exactly why those metrics diverge from weight. A stable or slowly rising weight during perimenopause can mask 2–3% yearly gains in visceral fat and concurrent loss of muscle. This matters because visceral fat is metabolically unfavourable—it correlates with markers you likely monitor: insulin sensitivity, inflammatory biomarkers, and lipid profiles.

The prescription offered here has two evidence-backed components. Exercise: 250 minutes weekly (split between ~150 min aerobic work and ~100 min strength training) reduces visceral fat in postmenopausal women; both modalities matter—aerobic work shifts fat mass, resistance training preserves and builds muscle. Nutrition: swapping saturated fats for unsaturated fats (olive oil, nuts, fatty fish) and increasing plant protein, without calorie restriction, showed a measurable reduction in visceral fat volume in a year-long trial. These fit neatly into trainable protocols rather than generic "eat less, move more" advice.

Caveats

• The visceral fat reduction from the NutriAct diet trial was modest in absolute terms (0.162 liters over a year) and only ~63% of randomized participants completed imaging
• The tissue biopsy study was small (n=33) and represents a signal, not conclusive evidence of mechanism
• The testosterone association with visceral fat is observational and cannot establish causation
• Exercise meta-analysis pooled heterogeneous trial designs with inconsistent visceral fat measurement methods, so effect sizes are not precisely quantified
• Most landmark studies included predominantly White and Black participants; applicability to other populations (e.g., Japanese women showed no significant fat gain) remains unclear
• None of this addresses whether visceral fat reduction translates to reduced disease risk in women taking hormonal therapies or other interventions